{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:34:28Z","timestamp":1791333268300,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1124\/jpet.112.193045","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T00:50:30Z","timestamp":1335487830000},"page":"288-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["KGA-2727, a Novel Selective Inhibitor of a High-Affinity Sodium Glucose Cotransporter (SGLT1), Exhibits Antidiabetic Efficacy in Rodent Models"],"prefix":"10.1016","volume":"342","author":[{"given":"Toshihide","family":"Shibazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tomae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ishikawa-Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Isaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.112.193045_bib1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.112.193045_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ajcn\/79.4.537","article-title":"Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity","volume":"79","author":"Bray","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/jpet.112.193045_bib3","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.193045_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1523-1755.2000.00836.x","article-title":"Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes","volume":"57","author":"Coimbra","year":"2000","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.112.193045_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinte.161.3.397","article-title":"Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria","volume":"161","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.112.193045_bib6","doi-asserted-by":"crossref","first-page":"479S","DOI":"10.1042\/bst025479s","article-title":"Changes in the levels of intestinal Na+\/glucose co-transporter (SGLT1) in experimental diabetes","volume":"25","author":"Dyer","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/jpet.112.193045_bib7","doi-asserted-by":"crossref","first-page":"G241","DOI":"10.1152\/ajpgi.00310.2001","article-title":"Expression of monosaccharide transporters in intestine of diabetic humans","volume":"282","author":"Dyer","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/jpet.112.193045_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1124\/jpet.112.193045_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1210\/er.2007-0015","article-title":"The role for endoplasmic reticulum stress in diabetes mellitus","volume":"29","author":"Eizirik","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1124\/jpet.112.193045_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.193045_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2009.03.007","article-title":"Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats","volume":"609","author":"Fujimori","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.112.193045_bib12","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s001250051092","article-title":"Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats","volume":"41","author":"Fujita","year":"1998","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.112.193045_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2009.09.048","article-title":"The \u03b1-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic \u03b2-cells in OLETF rats","volume":"624","author":"Fukaya","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.112.193045_bib14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1017\/S0007114507742678","article-title":"Effects of miglitol, an \u03b1-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats","volume":"98","author":"Goda","year":"2007","journal-title":"Br J Nutr"},{"key":"10.1124\/jpet.112.193045_bib15","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1002\/(SICI)1099-0895(199809)14:1+<S31::AID-DMR226>3.0.CO;2-3","article-title":"The evolving role of \u03b1-glucosidase inhibitors","volume":"14","author":"G\u00f6ke","year":"1998","journal-title":"Diabetes Metab Rev"},{"key":"10.1124\/jpet.112.193045_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na+-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"10.1124\/jpet.112.193045_bib17","series-title":"2011 Guideline for Management of Postmeal Glucose in Diabetes","year":"2011"},{"key":"10.1124\/jpet.112.193045_bib18","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/ki.2010.511","article-title":"SGLT2 inhibitors: molecular design and potential differences in effect","volume":"120","author":"Isaji","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1124\/jpet.112.193045_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2009.07.001","article-title":"Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice","volume":"618","author":"Katsuno","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.112.193045_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.193045_bib21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(09)60222-1","article-title":"Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance","volume":"373","author":"Kawamori","year":"2009","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.193045_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-642-17214-4_5","article-title":"SGLT inhibitors as new therapeutic tools in the treatment of diabetes","volume":"203","author":"Kinne","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.112.193045_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0026-0495(00)90242-7","article-title":"Inhibition of progressive reduction of islet \u03b2-cell mass in spontaneously diabetic Goto-Kakizaki rats by \u03b1-glucosidase inhibitor","volume":"49","author":"Koyama","year":"2000","journal-title":"Metabolism"},{"key":"10.1124\/jpet.112.193045_bib24","doi-asserted-by":"crossref","first-page":"690S","DOI":"10.1093\/ajcn\/59.3.690S","article-title":"Digestion and absorption of carbohydrates\u2013from molecules and membranes to humans","volume":"59","author":"Levin","year":"1994","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/jpet.112.193045_bib25","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.2337\/dc10-1079","article-title":"Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis","volume":"33","author":"Malik","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.112.193045_bib26","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.112.193045_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1124\/jpet.108.148056","article-title":"Chronic administration of voglibose, an \u03b1-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob\/ob mice","volume":"329","author":"Moritoh","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.193045_bib28","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"10.1124\/jpet.112.193045_bib29","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet \u03b2 cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.112.193045_bib30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3109\/00365529509101597","article-title":"Glucagon-like peptide 1 (7\u201336 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using \u03b1-glucosidase inhibition (acarbose)","volume":"30","author":"Qualmann","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1124\/jpet.112.193045_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2337\/diabetes.52.3.581","article-title":"Glucose toxicity in \u03b2-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection","volume":"52","author":"Robertson","year":"2003","journal-title":"Diabetes"},{"key":"10.1124\/jpet.112.193045_bib32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","article-title":"Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats","volume":"80","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.112.193045_bib33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bbrc.2005.08.158","article-title":"Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients","volume":"336","author":"Shiraiwa","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.112.193045_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/dmrr.903","article-title":"Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia","volume":"24","author":"Sugimoto","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1124\/jpet.112.193045_bib35","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.112.193045_bib36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/350354a0","article-title":"Glucose\/galactose malabsorption caused by a defect in the Na+\/glucose cotransporter","volume":"350","author":"Turk","year":"1991","journal-title":"Nature"},{"key":"10.1124\/jpet.112.193045_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.193045_bib38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/01.CIR.97.17.1695","article-title":"Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo","volume":"97","author":"Williams","year":"1998","journal-title":"Circulation"},{"key":"10.1124\/jpet.112.193045_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.diabres.2006.11.011","article-title":"Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels","volume":"77","author":"Woerle","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1124\/jpet.112.193045_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active sugar transport in health and disease","volume":"261","author":"Wright","year":"2007","journal-title":"J Intern Med"},{"key":"10.1124\/jpet.112.193045_bib41","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/138945007781386884","article-title":"Molecular mechanisms of diabetic nephropathy and its therapeutic intervention","volume":"8","author":"Yamagishi","year":"2007","journal-title":"Curr Drug Targets"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.112.193045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:09:46Z","timestamp":1739984986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524182961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0022356524182961"],"URL":"https:\/\/doi.org\/10.1124\/jpet.112.193045","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KGA-2727, a Novel Selective Inhibitor of a High-Affinity Sodium Glucose Cotransporter (SGLT1), Exhibits Antidiabetic Efficacy in Rodent Models","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.112.193045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}